Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Are there any new adjuvants in the 2025-2026 influenza vaccine?
Executive Summary
No authoritative source indicates that a brand-new adjuvant was added to routine 2025–2026 seasonal influenza vaccines; regulatory recommendations and product notes describe the continued use of existing adjuvanted vaccines rather than the introduction of novel, approved adjuvants. Independent laboratory research reports promising experimental adjuvants, but those studies do not show regulatory approval or inclusion in the 2025–2026 vaccine formulations [1] [2] [3].
1. Claims on the Table: Who’s Saying What and Why They Matter
The primary claims in the evidence set break into three threads: first, official vaccine composition guidance for 2025–2026 does not announce new adjuvants and focuses on strain selection (FDA and WHO communications in early 2025) [1] [4]. Second, public health program materials and national immunization summaries for 2025–2026 continue to reference existing adjuvanted products—for example, Fluad and high‑dose formulations—without listing any newly approved adjuvants (publication dates Sept–Oct 2025) [3] [5]. Third, academic and laboratory research papers during 2025 report novel adjuvant candidates and review evolving platforms, but these are experimental findings and review discussions rather than evidence of regulatory adoption into the season’s vaccine supply [2] [6].
2. What Regulators and Strain Recommendations Reveal About Add‑Ons
Regulatory and advisory documents that determine what manufacturers include in seasonal vaccines focus on antigenic strain composition, not adjuvant approvals, for the 2025–2026 northern hemisphere season; the FDA’s public recommendation in March–April 2025 centered on which virus strains to include and did not announce adjuvant changes [1] [7]. The World Health Organization’s composition guidance for the 2025–2026 season likewise specified strains, not novel adjuvant approvals [4]. Regulatory transparency typically requires separate, explicit approvals and communications when a manufacturer adds or changes an adjuvant; no such regulatory announcement appears among the cited official documents, which supports the conclusion that no new adjuvant was formally introduced for that season [1] [4].
3. Product Notes: Which Adjuvanted Vaccines Are Being Used Now
Country-level immunization program materials and vaccine supply reporting for late 2025 list continued deployment of existing adjuvanted vaccines—notably MF59‑adjuvanted Fluad for older adults and high-dose inactivated formulations for certain age groups—without citing a newly approved adjuvant chemistry or platform for 2025–2026 [3] [5]. These communications, dated September–October 2025, emphasize vaccine uptake and availability rather than novel formulation changes; this pattern indicates programmatic reliance on previously licensed adjuvants rather than adoption of experimental candidates discussed in academic literature [3] [5]. Manufacturers would need to pursue separate regulatory filings and clear public notices to change adjuvant use at scale.
4. Laboratory Breakthroughs and Why They Don’t Equate to Approved Vaccines
Academic research in 2025 highlights promising adjuvant innovations—examples include extracellular vesicles from mature dendritic cells that enhanced protection in preclinical models—yet these studies are preclinical or early‑stage and do not equate to licensed, market‑ready adjuvants [2]. Review articles published through mid‑2025 survey an expanding toolbox of adjuvant platforms (aluminum salts, oil‑in‑water emulsions like MF59 and AS03, TLR agonists, saponins, virosomes, and experimental nucleic acid approaches), but they explicitly note the gap between research and regulatory approval [6] [8]. The presence of novel adjuvant candidates in peer‑reviewed studies signals future possibilities and scientific momentum, but it is not evidence that such candidates were adopted into the standard 2025–2026 seasonal influenza vaccines [2] [6].
5. Contrasting Voices and Potential Agendas to Watch
Public health program communications and regulatory documents aim to reassure and guide vaccine delivery and therefore emphasize continuity and authorized products; their silence on new adjuvants suggests no formal change [3] [1]. Academic and institutional press on novel adjuvants often seeks funding, patenting, or translational partnerships and can highlight potential without clarifying regulatory timelines; therefore, claims rooted in laboratory findings should be read as promotional of future impact rather than confirmation of current practice [2] [6]. Independent reviewers and systematic surveys serve as a counterweight by explicitly stating when adjuvants are still under investigation and listing approved adjuvants that remain in use [8].
6. Bottom Line and What to Expect Next Season
Based on the available regulatory statements and national program materials through October 2025, there is no documented addition of a new, licensed adjuvant to the 2025–2026 influenza vaccine portfolio; existing adjuvanted vaccines continue to be used [1] [3]. Ongoing research identifies several promising adjuvant technologies that could influence future seasons, but manufacturers must complete clinical development and obtain explicit regulatory approvals before changing marketed formulations, and no such approvals appear in the cited documents for 2025–2026 [2] [8]. Monitor regulatory announcements and manufacturer product monographs for definitive updates; until then, treat laboratory breakthroughs as indicators of future innovation, not as evidence of current vaccine composition [7] [6].